secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123279
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical Q3 revenue $19.5M (+44% YoY); amends OrbiMed debt, removes $50M tranches
--------------------------------------------------------------------------------

- Commercial revenue $19.5M, up 44% YoY; gross margin 83.7% vs 84.5%.
- Net loss $16.2M ($0.62 loss per share) vs $8.7M loss in prior year quarter.
- Amended OrbiMed credit agreement: terminated two $50M tranches, removed Q4 2024 revenue covenant.
- Full-year 2024 revenue guidance reaffirmed at $68-70M (37-41% growth); Q4 guidance $22.3-24.3M.
- Expects RECELL GO mini FDA approval by Dec 31, 2024; Cohealyx launch Jan 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000095017024123279/0000950170-24-123279-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000095017024123279/rcel-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123279

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer